A phase II evaluation of tamoxifen in unresectable or refractory meningiomas

a southwest oncology group study

J. Wendall Goodwin, John Crowley, Harmon J. Eyre, Benjamin Stafford, Kurt Jaeckle, Jeannette J. Townsend

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5%) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32%) remained stable for a median duration of 31 + months while ten (53%) demonstrated progression. Twenty-two percent (22%) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a concensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalJournal of Neuro-Oncology
Volume15
Issue number1
DOIs
StatePublished - Jan 1 1993

Fingerprint

Meningioma
Tamoxifen
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Goodwin, J. W., Crowley, J., Eyre, H. J., Stafford, B., Jaeckle, K., & Townsend, J. J. (1993). A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study. Journal of Neuro-Oncology, 15(1), 75-77. https://doi.org/10.1007/BF01050266
Goodwin, J. Wendall ; Crowley, John ; Eyre, Harmon J. ; Stafford, Benjamin ; Jaeckle, Kurt ; Townsend, Jeannette J. / A phase II evaluation of tamoxifen in unresectable or refractory meningiomas : a southwest oncology group study. In: Journal of Neuro-Oncology. 1993 ; Vol. 15, No. 1. pp. 75-77.
@article{df328ca12c254977b77f17607ba45500,
title = "A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study",
abstract = "Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5{\%}) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32{\%}) remained stable for a median duration of 31 + months while ten (53{\%}) demonstrated progression. Twenty-two percent (22{\%}) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a concensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.",
author = "Goodwin, {J. Wendall} and John Crowley and Eyre, {Harmon J.} and Benjamin Stafford and Kurt Jaeckle and Townsend, {Jeannette J.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1007/BF01050266",
language = "English (US)",
volume = "15",
pages = "75--77",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

Goodwin, JW, Crowley, J, Eyre, HJ, Stafford, B, Jaeckle, K & Townsend, JJ 1993, 'A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study', Journal of Neuro-Oncology, vol. 15, no. 1, pp. 75-77. https://doi.org/10.1007/BF01050266

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas : a southwest oncology group study. / Goodwin, J. Wendall; Crowley, John; Eyre, Harmon J.; Stafford, Benjamin; Jaeckle, Kurt; Townsend, Jeannette J.

In: Journal of Neuro-Oncology, Vol. 15, No. 1, 01.01.1993, p. 75-77.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase II evaluation of tamoxifen in unresectable or refractory meningiomas

T2 - a southwest oncology group study

AU - Goodwin, J. Wendall

AU - Crowley, John

AU - Eyre, Harmon J.

AU - Stafford, Benjamin

AU - Jaeckle, Kurt

AU - Townsend, Jeannette J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5%) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32%) remained stable for a median duration of 31 + months while ten (53%) demonstrated progression. Twenty-two percent (22%) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a concensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.

AB - Twenty-one patients with nonresectable refractory meningiomas were registered on a study giving tamoxifen 40 mg per M2 b.i.d. for four days, then 10 mg b.i.d. thereafter. Nineteen were eligible and evaluated for response. One patient (5%) achieved an MRI-documented partial response while two had a minor response measured on CT scan which was of short duration (4 and 20 months). Six patients (32%) remained stable for a median duration of 31 + months while ten (53%) demonstrated progression. Twenty-two percent (22%) reported subjective improvement though this did not correlate with objective improvement in all cases. At present, a definite recommendation for the use of tamoxifen in refractory meningiomas cannot be made. Further evaluation of hormonal therapy of meningiomas with a concensus for definition of endpoints for evaluation of response in view of the difficulty of evaluating radiologic findings with clinical outcome, is needed.

UR - http://www.scopus.com/inward/record.url?scp=0027414013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027414013&partnerID=8YFLogxK

U2 - 10.1007/BF01050266

DO - 10.1007/BF01050266

M3 - Article

VL - 15

SP - 75

EP - 77

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -